Search

Your search keyword '"Hodgson, Darren"' showing total 211 results
Start Over Author "Hodgson, Darren"
211 results on '"Hodgson, Darren"'

1. Next-generation MRD assays: do we have the tools to evaluate them properly?

Author

Stetson, Dan, Labrousse, Paul, Russell, Hugh, Shera, David, Abbosh, Chris, Dougherty, Brian, Barrett, J. Carl, Hodgson, Darren, and Hadfield, James

Subjects
Quantitative Biology - Other Quantitative Biology
Abstract

Circulating tumour DNA (ctDNA) detection of molecular residual disease (MRD) in solid tumours correlates strongly with patient outcomes and is being adopted as a new clinical standard. ctDNA levels are known to correlate with tumor volume, and although the absolute levels vary across indication and histology, its analysis is driving the adoption of MRD. MRD assays must detect tumor when imaging cannot and, as such, require very high sensitivity to detect the low levels of ctDNA found after curative intent therapy. The minimum threshold is 0.01% Tumour Fraction but current methods like Archer and Signatera are limited by detection sensitivity resulting in some patients receiving a false negative call thereby missing out on earlier therapeutic intervention. Multiple vendors are increasing the number of somatic variants tracked in tumour-informed and personalized NGS assays, from tens to thousands of variants. Most recently, assays using other biological features of ctDNA, e.g methylation or fragmentome, have been developed at the LOD required for clinical utility. These uniformed, or tumour-naive and non-personalised assays may be more easily, and therefore more rapidly, adopted in the clinic. However, this rapid development in MRD assay technology results in significant challenges in benchmarking these new technologies for use in clinical trials. This is further complicated by the fact that previous reference materials have focused on somatic variants, and do not retain all of the epigenomic features assessed by newer technologies. In this Comments and Controversy paper, we detail what is known and what remains to be determined for optimal reference materials of MRD methods and provide opinions generated during three-years of MRD technology benchmarking in AstraZeneca Translational Medicine to help guide the community conversation.

Published
2023

3. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Author

Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., and Timms, Kirsten M.

Published
2023
Full Text
View/download PDF

6. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Author

Abbosh, Christopher, Frankell, Alexander M., Harrison, Thomas, Kisistok, Judit, Garnett, Aaron, Johnson, Laura, Veeriah, Selvaraju, Moreau, Mike, Chesh, Adrian, Chaunzwa, Tafadzwa L., Weiss, Jakob, Schroeder, Morgan R., Ward, Sophia, Grigoriadis, Kristiana, Shahpurwalla, Aamir, Litchfield, Kevin, Puttick, Clare, Biswas, Dhruva, Karasaki, Takahiro, Black, James R. M., Martínez-Ruiz, Carlos, Bakir, Maise Al, Pich, Oriol, Watkins, Thomas B. K., Lim, Emilia L., Huebner, Ariana, Moore, David A., Godin-Heymann, Nadia, L’Hernault, Anne, Bye, Hannah, Odell, Aaron, Roberts, Paula, Gomes, Fabio, Patel, Akshay J., Manzano, Elizabeth, Hiley, Crispin T., Carey, Nicolas, Riley, Joan, Cook, Daniel E., Hodgson, Darren, Stetson, Daniel, Barrett, J. Carl, Kortlever, Roderik M., Evan, Gerard I., Hackshaw, Allan, Daber, Robert D., Shaw, Jacqui A., Aerts, Hugo J. W. L., Licon, Abel, Stahl, Josh, Jamal-Hanjani, Mariam, Birkbak, Nicolai J., McGranahan, Nicholas, and Swanton, Charles

Published
2023
Full Text
View/download PDF

8. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

Author

Willis, Sophie E., Winkler, Claudia, Roudier, Martine P., Baird, Tarrion, Marco-Casanova, Paola, Jones, Emma V., Rowe, Philip, Rodriguez-Canales, Jaime, Angell, Helen K., Ng, Felicia S. L., Waring, Paul M., Hodgson, Darren, Ledermann, Jonathan A., Weberpals, Johanne I., Dean, Emma, Harrington, Elizabeth A., Barrett, J. Carl, Pierce, Andrew J., Leo, Elisabetta, and Jones, Gemma N.

Published
2021
Full Text
View/download PDF

9. Tumor-naïve pre-surgical ctDNA detection is prognostic in clinical stage I lung adenocarcinoma

Author

Hong, Tae Hee, primary, Hwang, Soohyun, additional, Dasgupta, Abhijit, additional, Abbosh, Christopher, additional, Hung, Tiffany, additional, Bredno, Jörg, additional, Walker, Jill, additional, Shi, Xiaojin, additional, Milenkova, Tsveta, additional, Horn, Leora, additional, Choi, Joon Young, additional, Lee, Ho Yun, additional, Cho, Jong Ho, additional, Choi, Yong Soo, additional, Shim, Young Mog, additional, Chai, Shoujie, additional, Rhodes, Kate, additional, Roychowdhury-Saha, Manami, additional, Hodgson, Darren, additional, Kim, Hong Kwan, additional, and Ahn, Myung, additional

Published
2024
Full Text
View/download PDF

10. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

Author

Powles, Thomas, Carroll, Danielle, Chowdhury, Simon, Gravis, Gwenaelle, Joly, Florence, Carles, Joan, Fléchon, Aude, Maroto, Pablo, Petrylak, Daniel, Rolland, Frédéric, Cook, Natalie, Balar, Arjun V., Sridhar, Srikala S., Galsky, Matthew D., Grivas, Petros, Ravaud, Alain, Jones, Robert, Cosaert, Jan, Hodgson, Darren, Kozarewa, Iwanka, Mather, Richard, McEwen, Robert, Mercier, Florence, and Landers, Dónal

Published
2021
Full Text
View/download PDF

12. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Author

Vega, Diana Merino, Nishimura, Katherine K., Zariffa, Névine, Thompson, Jeffrey C., Hoering, Antje, Cilento, Vanessa, Rosenthal, Adam, Anagnostou, Valsamo, Baden, Jonathan, Beaver, Julia A., Chaudhuri, Aadel A., Chudova, Darya, Fine, Alexander D., Fiore, Joseph, Hodge, Rachel, Hodgson, Darren, Hunkapiller, Nathan, Klass, Daniel M., Kobie, Julie, Peña, Carol, Pennello, Gene, Peterman, Neil, Philip, Reena, Quinn, Katie J., Raben, David, Rosner, Gary L., Sausen, Mark, Tezcan, Ayse, Xia, Qi, Yi, Jing, Young, Amanda G., Stewart, Mark D., Carpenter, Erica L., Aggarwal, Charu, and Allen, Jeff

Published
2022
Full Text
View/download PDF

15. The landscape ofBRCA1andBRCA2large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing

Author

Jones, Melanie A., primary, Timms, Kirsten M., additional, Hatcher, Shanell, additional, Cogan, Elizabeth S., additional, Comeaux, Matthew S., additional, Perry, Michael, additional, Morris, Brian, additional, Swedlund, Brad, additional, Elks, Cathy E., additional, Lao‐Sirieix, Pierre, additional, Dearden, Simon, additional, Egile, Coumaran, additional, Brown, Jessica S., additional, Harrington, Elizabeth A., additional, Hodgson, Darren, additional, Stern, Matt, additional, Slavin, Thomas P., additional, and Mancini‐DiNardo, Debora, additional

Published
2023
Full Text
View/download PDF

17. Abstract 3369: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies

Author

Munugalavadla, Veerendra, primary, de Jesus, Gary, additional, Markovets, Aleksandra, additional, Liu, Qinwen, additional, Venn, Oliver, additional, White, Rafael, additional, Fabbri, Giulia, additional, Labrousse, Paul, additional, Stetson, Dan, additional, Dougherty, Brian, additional, Hodgson, Darren, additional, Walker, Jill, additional, Younes, Anas, additional, and Auclair, Daniel, additional

Published
2023
Full Text
View/download PDF

18. Abstract 3384: Evaluation of a tumor informed MRD assay with contrived breast cancer samples

Author

Russell, Hugh, primary, LaBrousse, Paul, additional, Stetson, Daniel, additional, Jones, Greg, additional, Marsico, Giovanni, additional, Forshew, Tim, additional, McEwen, Robert, additional, De Bruin, Elza, additional, Abbosh, Christopher, additional, Hodgson, Darren, additional, Dougherty, Brian, additional, Hadfield, James, additional, and Barrett, Carl, additional

Published
2023
Full Text
View/download PDF

19. Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Author

Brant, Roz, primary, Sharpe, Alan, primary, Liptrot, Tom, primary, Dry, Jonathan R., primary, Harrington, Elizabeth A., primary, Barrett, J. Carl, primary, Whalley, Nicky, primary, Womack, Christopher, primary, Smith, Paul, primary, and Hodgson, Darren R., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 7 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 6 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 2 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures 8-12 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

30. Data from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table and Figure Legends from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 4 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 3 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 5 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

36. Supplementary References from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 1 from Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Author

Dry, Jonathan R., primary, Pavey, Sandra, primary, Pratilas, Christine A., primary, Harbron, Chris, primary, Runswick, Sarah, primary, Hodgson, Darren, primary, Chresta, Christine, primary, McCormack, Rose, primary, Byrne, Natalie, primary, Cockerill, Mark, primary, Graham, Alexander, primary, Beran, Garry, primary, Cassidy, Andrew, primary, Haggerty, Carolyn, primary, Brown, Helen, primary, Ellison, Gillian, primary, Dering, Judy, primary, Taylor, Barry S., primary, Stark, Mitchell, primary, Bonazzi, Vanessa, primary, Ravishankar, Sugandha, primary, Packer, Leisl, primary, Xing, Feng, primary, Solit, David B., primary, Finn, Richard S., primary, Rosen, Neal, primary, Hayward, Nicholas K., primary, French, Tim, primary, and Smith, Paul D., primary

Published
2023
Full Text
View/download PDF

38. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Author

Ledermann, Jonathan A, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Spencer, Stuart, Rowe, Philip, Lowe, Elizabeth, Hodgson, Darren, Sovak, Mika A, and Matulonis, Ursula

Published
2016
Full Text
View/download PDF

39. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next‐generation sequencing.

Author

Jones, Melanie A., Timms, Kirsten M., Hatcher, Shanell, Cogan, Elizabeth S., Comeaux, Matthew S., Perry, Michael, Morris, Brian, Swedlund, Brad, Elks, Cathy E., Lao‐Sirieix, Pierre, Dearden, Simon, Egile, Coumaran, Brown, Jessica S., Harrington, Elizabeth A., Hodgson, Darren, Stern, Matt, Slavin, Thomas P., and Mancini‐DiNardo, Debora

Published
2023
Full Text
View/download PDF

41. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Author

Ledermann, Jonathan, Harter, Philipp, Gourley, Charlie, Friedlander, Michael, Vergote, Ignace, Rustin, Gordon, Scott, Clare L, Meier, Werner, Shapira-Frommer, Ronnie, Safra, Tamar, Matei, Daniela, Fielding, Anitra, Spencer, Stuart, Dougherty, Brian, Orr, Maria, Hodgson, Darren, Barrett, J Carl, and Matulonis, Ursula

Published
2014
Full Text
View/download PDF

44. Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Author

Hodgson, Darren R., primary, Brown, Jessica S., additional, Dearden, Simon P., additional, Lai, Zhongwu, additional, Elks, Cathy E., additional, Milenkova, Tsveta, additional, Dougherty, Brian A., additional, Lanchbury, Jerry S., additional, Perry, Michael, additional, Timms, Kirsten M., additional, Harrington, Elizabeth A., additional, Barrett, J. Carl, additional, Leary, Alexandra, additional, and Pujade-Lauraine, Eric, additional

Published
2021
Full Text
View/download PDF

45. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer

Author

Carr, T. Hedley, primary, Adelman, Carrie, additional, Barnicle, Alan, additional, Kozarewa, Iwanka, additional, Luke, Sally, additional, Lai, Zhongwu, additional, Hollis, Sally, additional, Dougherty, Brian, additional, Harrington, Elizabeth A., additional, Kang, Jinyu, additional, Saad, Fred, additional, Sala, Nuria, additional, Thiery-Vuillemin, Antoine, additional, Clarke, Noel W., additional, Hodgson, Darren, additional, and Barrett, J. Carl, additional

Published
2021
Full Text
View/download PDF

47. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer

Author

Weberpals, Johanne I., primary, Pugh, Trevor J., additional, Marco‐Casanova, Paola, additional, Goss, Glenwood D., additional, Andrews Wright, Natalie, additional, Rath, Prisni, additional, Torchia, Jonathon, additional, Fortuna, Alexander, additional, Jones, Gemma N., additional, Roudier, Martine P., additional, Bernard, Laurence, additional, Lo, Bryan, additional, Torti, Dax, additional, Leon, Alberto, additional, Marsh, Kayla, additional, Hodgson, Darren, additional, Duciaume, Marc, additional, Howat, William J., additional, Lukashchuk, Natalia, additional, Lazic, Stanley E., additional, Whelan, Doreen, additional, and Sekhon, Harmanjatinder S., additional

Published
2021
Full Text
View/download PDF

50. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma

Author

Gupta, Avinash, primary, Towers, Christopher, additional, Willenbrock, Frances, additional, Brant, Roz, additional, Hodgson, Darren Richard, additional, Sharpe, Alan, additional, Smith, Paul, additional, Cutts, Anthony, additional, Schuh, Anna, additional, Asher, Ruth, additional, Myers, Kevin, additional, Love, Sharon, additional, Collins, Linda, additional, Wise, Adelyn, additional, Middleton, Mark Roy, additional, and Macaulay, Valentine Moya, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results